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Objective: The present article aims to provide a systematic review of the influence of 
anti-tumor necrosis factor (TNF) on infection rates in patients with rheumatoid arthri-
tis (RA).
Method: Medline was searched to obtain quality control information on infection rates 
in RA patients treated with anti-TNF.
Results: A high proportion of RA patients are now established users of anti-TNF agents. 
Data from national registries in European countries of patients with RA treated with an-
ti-TNF suggest that biological therapies are closely linked to sepsis. Although previous 
studies reported a higher risk of infections, there are now emerging data with longer 
duration of follow-up that suggested an adjusted hazard risk of 1.2. Elderly patients and 
those with longstanding disease may have a higher rate of serious infections compared 
to their counterparts who were younger with early disease. There are now emerging 
data to suggest that anti-TNF therapy is associated with the development of neutrope-
nia shortly after the commencement of treatment. The biologic registries found that RA 
patients treated with monoclonal antibodies are at increased risk of tuberculosis (TB) 
compared to those on TNF receptor blockers. This risk of infection needs to be weighed 
against the established benefits of TNF blockers. 
Conclusion: Current evidence suggests that anti-TNF treatment in RA is closely linked 
to infection. Patients need to be aware of the risk of infection together with the estab-
lished benefits of TNF blockers in order to give informed consent for treatment.
© 2013 Elsevier Editora Ltda. All rights reserved.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disor-
der involving synovial joints that affects over 400,000 peo-
ple in the United Kingdom. Women are more than twice as 
likely to be affected compared to men.1 In Brazil, RA affects 
up to 1% of the population with an estimated 1,300,000 suf-
ferers.2
In 1972, O’Sullivan et al. reported the result of a popula-
tion-based study where 72% of the RA patients who fulfilled 
the American Rheumatism Association (ARA) 1958 criteria 
had no clinical signs of RA at follow-up three to five years 
later.3 It is not surprising, therefore, that the pyramidal ap-
proach4,5 was widely adopted in the treatment of RA. This 
is based on the assumptions that RA is a benign condition 
and that disease-modifying antirheumatic drugs (DMARDs) 
have high incidence of toxicity. In this traditional treatment 
paradigm, aspirin and non-steroidal anti-inflammatory 
drugs (NSAIDs) are used initially to control inflammation. 
DMARDs are offered to patients with more severe disease. 
Current evidence suggests that this has changed, and that 
disease-modifying treatments are started earlier rather 
than later in the management of RA.
Tumor necrosis factor alpha (TNF-α) is a potent inflam-
matory cytokine found in high titer in the synovial fluid of 
RA patients.6 Anti-tumor necrosis factor (anti-TNF) thera-
pies have revolutionized the way RA is managed. Evidence 
shows that patients treated early with anti-TNF therapies 
have less radiographic progression and better functional 
outcome.7 With the availability of effective therapies, it is 
likely that, in the foreseeable future, many patients will be 
managed with TNF blockers.
One of the main concerns regarding anti-TNF treatment 
is the adverse consequences of TNF inhibition. TNF is a me-
diator in the normal inflammatory pathway8 and has bac-
tericidal properties.9 Therefore, TNF blockers may cause se-
vere immunosuppression.
Conversely, previous clinical trials have demonstrated 
that in patients with sepsis, anti-TNF may promote a small 
survival benefit.10-12 However, these findings were not repli-
cated in other studies.13,14
This study aimed to review the available clinical evi-
dence on the influence of anti-TNF on infection rates in RA 
patients. 
Methods
In this review, Medline (ŚƩƉ͗ͬͬǁǁǁ͘ƉƵďŵĞĚ͘ŐŽǀ) as the main 
search engine. If the number of hits exceeded 375, the re-
view of articles would be restricted using the “core clinical 
journals” subset function and those published in the last 
ten years. The inclusion criteria were articles pertaining 
to human subjects and published in English language. The 
Medical Subject Headings [MeSH] database was consulted 
to search for the best keywords. The Boolean operator “AND” 
together with “OR” were used when combining two or three 
keywords. Only articles regarding the first generation anti-
TNF agents with the highest level of evidence were selected 
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Resumo: O presente trabalho tem como objetivo fornecer uma análise sistemática da influ-
ência do anti-TNF sobre as taxas de infecção em pacientes com artrite reumatoide (AR).
Método: Pesquisamos na Medline para obter informações de controle de qualidade sobre as 
taxas de infecção em pacientes com AR tratados com anti-TNF.
Resultados: Atualmente, uma proporção elevada de pacientes com AR é usuária de agentes 
anti-TNF. Dados de registros nacionais em países da Europa de pacientes com AR tratados 
com anti-TNF sugerem que terapias biológicas estão intimamente ligadas à sepse. Apesar 
de estudos anteriores terem relatado um maior risco de infecções, atualmente há dados 
emergentes com maior duração de acompanhamento que sugerem um risco ajustado de 
1,2. Os pacientes idosos e os com doença de longa data poderão apresentar uma taxa mais 
elevada de infecções graves em comparação às suas contrapartes mais novas com doença 
inicial. Hoje, há dados emergentes que sugerem que a terapia com anti-TNF está asso-
ciada ao desenvolvimento de neutropenia logo após o início do tratamento. Os registros 
biológicos constataram que os pacientes com ARES tratados com anticorpos monoclonais 
apresentam aumento no risco de tuberculose (TB), em comparação aos tratados com blo-
queadores dos receptores de TNF. Esse risco de infecção precisa ser ponderado em relação 
aos benefícios estabelecidos dos bloqueadores de TNF. 
Conclusão: A evidência atual sugere que o tratamento com anti-TNF na AR está intimamen-
te associado à infecção. Os pacientes precisam estar cientes do risco de infecção, assim 
como dos benefícios estabelecidos dos bloqueadores de TNF, para que possam fornecer o 
consentimento informado para o tratamento.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
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and reviewed in detail. The references of the retrieved ar-
ticles were also consulted.
Infection in RA
(“Infection” [MeSH] OR “Adverse effects”) AND “Rheumatoid 
arthritis” [MeSH] AND “Risk factors”
Infection and anti-TNF in RA
a) (“Rheumatoid arthritis” [MeSH] AND “infliximab”) then 
(“Rheumatoid arthritis” [MeSH] AND “etanercept”) then 
(“Rheumatoid arthritis” [MeSH] AND “adalimumab”).
b) (“Infection [MeSH]” OR “Adverse effects”) AND (“inflix-
imab” OR “etanercept” OR “adalimumab”) AND “Rheuma-
toid arthritis” [MeSH].
Anti-TNF and neutropenia
“Tumor Necrosis Factor-alpha/antagonists and inhibitors” 
[MeSH] e “neutropenia”.
The results of the literature search are shown in Table 1.
were prospectively followed up for a median of seven years. 
There were a total of 34,250 RA patients and 102,747 con-
trols: 321 septic arthritis cases were identified during the 
study period. Of these, 236 occurred in those after the diag-
nosis of RA compared to 85 in controls. One-third of the RA 
patients with septic arthritis were not on DMARDs or pred-
nisone two months prior to the diagnosis of septic arthritis. 
The respective septic arthritis incidences for RA cases and 
controls were 1.31 (95% CI: 1.22-1.41) and 0.11 (95% CI: 0.09-
0.12) per 1,000 person-years. Exploratory analysis found that 
the increased incidence of septic arthritis occurred even be-
fore the diagnosis of RA. Prednisolone was associated with 
increased risk of septic arthritis with incidence rate ratio of 
2.94 (95% CI: 1.93-4.46).
In another study, Wolfe et al. found that each ten-year in-
crease in age or disease duration, history of smoking, isch-
aemic heart disease, and each additional previous DMARD 
use was found to be a predictor of pneumonic hospitaliza-
tion.18 High-dose steroid was found to be associated with 
sepsis in a dose-dependent manner.18,19 Bernatsky et al.20 
found that the relative risk (RR) of infections requiring hos-
pitalization for glucocorticoid agents was estimated to be 
2.56 (95% CI: 2.29-2.85). 
Summary of evidence for risk of infection in RA patients
RA patients are at an inherently increased risk of infec-
tion due to immune dysfunction.15,17 The available evidence 
demonstrates that the risk of infection in RA patients rises 
with increasing age, leucopenia, extra-articular features, 
and co-morbidities.16 High dose steroids17-20 and history of 
smoking18 were found to be sepsis predictors. For patients 
managed with prednisone, dosage reduction should be 
considered in order to minimise the risk of infection. Bone, 
joint, skin, and respiratory tract are the commonest sites of 
infection.
Rheumatoid arthritis, TNF blockers, and infections
Randomised controlled trial (RCT)
Infliximab. In the Anti-TNF Trial in Rheumatoid Arthritis 
with Combination Therapy (ATTRACT) trial, 428 active RA 
patients refractory to methotrextate (MTX), were random-
ized to receive infliximab (3 or 10 mg/kg every four or eight 
weeks plus MTX); and the fifth group was treated with MTX 
and placebo for 54 weeks.21 The frequency of serious infec-
tions was comparable between those that received MTX/in-
fliximab and those treated with MTX.
The BeST study was designed to examine the effect of 
infliximab in early RA. 508 early RA patients were randomly 
assigned to sequential monotherapy, step-up combination 
therapy, step-down therapy, or infliximab with MTX.22. There 
were no significant differences in the number of adverse 
infectious events between the four groups during the first 
year of follow-up. Infections, predominantly in the upper 
respiratory tract, were observed in 4%, 7%, 8%, and 8% of 
subjects, respectively.
In a randomized placebo control trial (START), 1,084 
patients with RA on MTX were randomized to receive in-
Table 1 – Results of search.
Number of 
hits
Number of 
articles reviewed 
in detail
Infection and anti-TNF in RA 171 6
a) RA and infliximab 345 4
RA and etanercept 281 4
RA and adalimumab 140 4
b) Infecção, anti-TNF e AR 244 26
Anti-TNF e neutropenia 22 5
RA, rheumatoid arthritis; TNF, tumor necrosis factor.
Results
Rheumatoid arthritis and risk of infections
In 2002, Doran et al.15 reported the result of a population-based 
study where the frequencies of infection in RA patients were 
compared to controls. The participants were followed-up for 
over ten years. There were a total of 1,218 participants (609 RA 
and an equivalent number of non-RA subjects). The overall rate 
of infection requiring hospitalization was 9.57 per 100 person-
years in RA patients compared to 5.07 per 100 person-years in 
non-RA subjects. The hazard ratio (HR) for infection requiring 
hospital admission was 1.83 (95% CI: 1.52-2.21), while that for 
objectively confirmed infection was 1.70 (95% CI: 1.42-2.03). The 
commonest sites of serious infection in RA patients were septic 
arthritis, followed by osteomyelitis and soft tissue. The same 
group found that increasing age, leucopenia, disease severity 
factors (i.e. rheumatoid factor positivity, rheumatoid nodules, 
raised ESR), and co-morbidities (i.e. diabetes and chronic lung 
disease) were predictors of serious infection.16
In the study by Edward et al.,17 RA patients and their 
matched-controls were identified using the United Kingdom 
General Practice Research Database (GPRD). Participants 
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fliximab 3 mg/kg, infliximab 10 mg/kg, or placebo.23 At 22 
weeks, the relative risk of serious infection in those treated 
with the 3 mg/kg and 10 mg/kg dose of infliximab were 1 
(95% CI: 0.3-3.1) and 3.1 (95% CI: 1.2-7.9), respectively. Infec-
tion of the respiratory tract was the commonest infectious 
adverse event.
In another large study, the Active controlled Study of 
Patients receiving infliximab for the treatment of Rheuma-
toid arthritis of Early onset (ASPIRE), 1,049 patients were 
randomized to receive infliximab 3 mg/kg, infliximab 6 mg/
kg, or placebo. All patients received concomitant MTX.24 
Patients were followed-up for 54 weeks. There were signifi-
cantly more serious infections in patients who were receiv-
ing a combination of MTX/infliximab 3 mg/kg and MTX/inf-
liximab 6 mg/kg when compared to those treated with MTX 
alone, with respective P-values of 0.02 and 0.04.
Etanercept. Moreland et al. performed a long-term open-la-
bel study to examine the efficacy and safety of etanercept 
in patients with established disease.25 The participants in 
this study were recruited from previous double-blinded 
controlled and open-label studies. There were a total of 628 
patients treated for a median of 25 months. The infective 
rate was 4.8 per 100 patient-years in users of etanercept, 
which was comparable to those on placebo (5 per 100 pa-
tient-years).
In another study, Gernovese et al.26 performed a random-
ized controlled study in early RA to investigate the effects of 
etanercept on both safety and efficacy. Patients with active 
disease were randomly assigned to receive MTX or etaner-
cept at a dose of 10 mg or 25 mg twice weekly. At the begin-
ning of the third year, patients on MTX and 10 mg of etan-
ercept went on to treatment with etanercept 25 mg twice 
per week, while those on etanercept 25 mg twice per week 
continued on the same regime. A total of 632 patients par-
ticipated at the start of the study and five-year data were 
available for 293 patients. The overall rate of serious infec-
tion was 2.6 events per 100 patient-years in those who re-
ceived etanercept, which was comparable to MTX group (3.1 
events per 100 patient-years) in the first year of the study.
In the COmbination of MTX and Etanercept (COMET) 
study,27 542 RA patients with disease duration of less than 
2 years who were MTX naïve were randomized to treat-
ment with MTX or a combination of etanercept and MTX. 
Patients were followed-up for 24 months. Adverse events 
were similar between the two groups. Eight patients (3%) 
in the monotherapy group and five (2%) in the combination 
therapy group developed serious infections.
In another study (TEMPO trial) of three years duration, 
682 RA patients with longer disease duration (mean disease 
duration of 6.8 years) were randomized to etanercept, MTX, 
or combination of etanercept with MTX.28. There were no 
differences in incidence of serious infections between the 
three groups.
Adalimumab. The Safety Trial of Adalimumab in RA (STAR) 
study was performed to investigate the safety and efficacy 
of adalimumab in RA patients treated with concomitant 
therapy.29 In that study, 636 RA patients were randomized 
to treatment with adalimumab 40 mg every other week, or 
placebo for 24 weeks. Patients continued to receive their ba-
sic antirheumatic treatment. The mean age was 55.4 years, 
with mean disease duration of 10.4 years. Infectious adverse 
events were comparable between the two groups. The rate 
of serious infection was 0.028 patients per patient-year in 
the adalimumab group, while in the placebo group it was 
0.046 patients per patient-year.
In the ARMADA study, 271 RA patients were randomly 
assigned to receive placebo or adalimumab 20 mg, 40 mg, 
or 80 mg every other week.30 There were 271 RA patients 
with mean disease duration of 12.3 years and mean age of 
55.5 years. The study period was 24 weeks. Infection rates 
were similar between those treated with adalimumab (1.55/
patient-year) and those who received placebo (1.38/patient-
year).
In the PREMIER study, 799 RA patients with disease du-
ration of less than 36 months were randomized to a com-
bination of MTX/adalimumab, monotherapy adalimumab, 
or oral MTX for a period of two years.31 The rate of serious 
infections in the combination group was 2.9 events per 100 
patient-years. This was significantly higher compared to the 
adalimumab monotherapy group, but not significantly dif-
ferent from the MTX monotherapy group.
Keystone at al. performed a double-blinded randomized 
placebo control trial where 619 RA patients were random-
ized to receive treatment with adalimumab plus MTX or 
MTX alone for 52 weeks.32 The patients had inadequate re-
sponse to MTX with mean disease duration of 10.9 years. 
There were significantly more patients treated with adali-
mumab who developed serious infections compared to pla-
cebo (3.8% vs. 0.5%, P < 0.02).
Non-randomized controlled trial
Wolfe et al.18 performed a prospective cohort study where 
16,788 RA patients were assessed semi-annually for 3.5 
years (Table 2). The participants were patients identified 
from the National Data Bank for Rheumatic Diseases (NDB). 
This study showed no increase in pneumonic risk in pa-
tients treated with anti-TNF (hazard ratio [HR] infliximab, 
1.2 [95% CI: 0.9 to 1.4]; etanercept, 0.8 [95% CI: 0.6 to 1], and 
adalimumab, 1.1 [95% CI: 0.6 to 1.8]). There was no increased 
risk of pneumonia amongst users of MTX and sulphasala-
zine. Again, the study found an increase in hospitalization 
for pneumonia in patients managed with prednisolone in a 
dose-response manner. The authors also reported a HR of 
1.2 (95% CI: 1 to 1.5) for leflunomide.
In the United States, Schneeweiss et al.19 performed a 
prospective cohort study on 15,597 RA patients aged 65 and 
over, where the risk of serious bacterial infections in those 
treated with TNF blockers was compared with users of other 
DMARDs. The results demonstrated that the risk of bacterial 
infections was similar in subjects receiving anti-TNF versus 
those treated with MTX. The rate of serious infections was 
more notable in the first 90 days after initiation of gluco-
corticoids and cytotoxic DMARDs. Treatment with gluco-
corticoids at a dosage of less that 5 mg was not associated 
with sepsis, but higher doses followed a dose-response rela-
tionship. Patients treated with anti-TNF were more likely to 
have undergone orthopedic surgery, indicating the severity 
of the rheumatoid process. However, this study was limited 
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Table 2 – National registries/observational studies of patients with rheumatoid arthritis treated with anti-TNF therapy.
First author, year 
of publication, 
journal title, 
country of origin
Type of study
e.g.: RCT,
cohort, case- 
control, cross 
sectional 
surveys, case 
report, reviews
Mean age (yrs) Disease 
duration (yrs) 
(Mean unless 
otherwise 
stated)
Sample size Duration of 
follow-up 
Study 
population
Key findings Serious 
infections rate  
per 100 PY(95 
% CI) (unless 
otherwise 
stated)
Respiratory 
infection
Skin infection Others
Wolfe et al. 
(USNDB), 
2006,[18] Arthritis 
Rheum, United 
States
Prospective 
observational 
study
62 16.3 USNDB =  16,788,
Non-registry =  
9,619
3.5 years Tx with anti-
TNF versus 
DMARD 
versus 
prednisolone
No increase in 
pneumonia risk 
with anti-TNF
Overall:
USNDB = 1.7 
(1.6-1.9)
Non-registry = 1.5 
(1.3-1.6)
HR (95% CI) 
pneumonia:
INF 1.2 (0.9-1.4)
ETA 0.8 (0.6-1.1)
ADA 1.1 (0.6-1.9)
_____ _____
Schneeweiss et al., 
2007,[19] Arthritis 
Rheum, United 
States
Retrospective 
cohort study
76.5 _____ Anti-TNF = 469,
Control (MTX) = 
1,900
Mean years-
Anti-TNF = 1.29,
MTX = 0.58
Tx with anti-
TNF versus 
MTX
No increase in 
serious infections 
reported between 
the two groups
Anti-TNF = 4.89 
(3.15-6.62)
MTX= 3.77 (2.64-
4.90)
The RR* for 
pneumonia was 
0.78 (0.28-2.13) 
when compared 
to treatment with 
MTX
____ The RR* for 
osteomyelitis was 
0.9 (0.14- 5.79) 
when compared to 
treatment with MTX
Kievit et al., 
2010,[33] 
Rheumatology, 
Nethelands
Prospective 
observational 
study
INF = 57
ADA = 54
ETA = 55
5.5-6.2 1,560 33 to 40 months Tx with anti-
TNF
The benefit to risk 
ratio for anti-TNF is 
favorable
Anti-TNF = 2.9 34 URTI 24 skin infections Eight joint infections
Listing et al. 
(RABBIT) 
2005,[34] Arthritis 
Rheum, Germany
Long-term 
prospective 
cohort study
INF = 53.6
ETA = 53.7
Control = 56.5
IFN = 8
ETA = 9
Control = 6
INF = 346
ETA = 512
Control = 601
12 months Tx with INF or 
ETA versus 
traditional 
DMARD 
(control)
Infections occurred in 
15%, 21%, and 6% of 
patients receiving 
ETA, INF, and 
traditional DMARD, 
respectively
DMARD = 2.28 
(1.3-3.9)
ETA = 6.42 (4.5- 
9.1)
INF = 6.15  (4-9.5)
Exposed group 
= 14 cases of 
pneumonia 
(versus three in 
control).  Exposed 
group = 32 upper 
respiratory tract 
infections (versus 
one in control)
Four, six, eight, 
and six patients 
developed 
erysipelas, 
furuncle, 
abscess, and 
paronychia (total 
24), respectively, 
in the anti-
TNF groups, 
compared to 
three in controls
Exposed group = 
six cases of septic 
arthritis (ETA = five, 
INF = one) compared 
to one in the control 
group
(continued on next page)
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Table 2 – National registries/observational studies of patients with rheumatoid arthritis treated with anti-TNF therapy (continued).
First author, year 
of publication, 
journal title, 
country of origin
Type of study
e.g.: RCT,
cohort, case- 
control, cross 
sectional 
surveys, case 
report, reviews
Mean age (yrs) Disease 
duration (yrs) 
(Mean unless 
otherwise 
stated)
Sample size Duration of 
follow-up 
Study 
population
Key findings Serious 
infections rate  
per 100 PY(95 
% CI) (unless 
otherwise 
stated)
Respiratory 
infection
Skin infection Others
Dixon et al.  
(BSRBR), 2006, [35] 
Arthritis Rheum, 
United Kingdom
Prospective 
observational 
study
Anti-TNF = 56,
DMARD = 60
Anti-TNF = 12,
DMARD = 6
Anti-TNF = 7,664
DMARD only = 
1,354
Anti-TNF = 1.26 
years, Controls 
= 0.94 years
Tx with 
anti¬TNF 
versus 
traditional 
DMARD
No significant 
differences in 
the risk of overall 
serious infections 
were observed.  
However, rate 
of serious skin 
and soft tissue 
infections was 
raised
INF = 6.89 (6.24-
7.60)
ETA = 6.17 (5.60-
6.78)
ADA = 5.42 (4.55-
6.40)
The IRR for 
respiratory 
infection for 
anti-TNF patients 
was 0.77 (95% CI 
0.46-1.11)
The IRR was 4.28 
(95% CI: 1.06-
17.17).  There 
were 118 skin 
infections, of 
which four (3.4%) 
were reported 
within 30 days  
of surgery
The IRR for bone/
joint and urinary 
tract infections 
were 1.12 (95% CI: 
0.32-3.88) and 1.70 
(95% CI: 0.32-9.03), 
respectively
Salliot et al., 
2007,[36] 
Rheumatology, 
France
Retrospective 
observational 
study
Anti-TNF = 45.9
Control = 46.5
Anti-TNF = 
11.8,
Control = 12.1
Anti-TNF (FU) 
= 709,
Control (FU + 
control period) 
= 623
1.7 years Anti-TNF = 
infection rates 
during Tx 
with anti-TNF
Control = 
infection rates 
before and 
during Tx 
with anti-TNF
Infections are 
frequently 
observed with 
anti-TNF.
Incidence rates:
Anti-TNF = 10.4+/-
82.1
Control = 
Before =3.4+/-38.7
During = 10.5+/- 
86.9
______ _______ _______
Inanc et al., 
2006,[37] 
Rheumatol Int, 
Turkey
Prospective cohort 
study
Anti-TNF = 52
DMARD = 55
Anti-TNF=
14 (median)
DMARD=
12 (median)
Anti-TNF= 48
DMARD=130
Median duration 
of Tx in 
anti-TNF = 19 
months
Tx with anti-
TNF versus 
DMARDs
Anti-TNF is 
associated with 
an increased 
risk of infections 
compared to  
DMARDs
Incidence:
Anti-TNF = 17,
DMARDs = 8.6
Incidence per 
100 PY for 
pneumonia:
Anti-TNF = 4
DMARDs = 0.7
Incidence per 
100 PY for skin 
infection:
Anti-TNF= 0
DMARDs = 0.2
Incidence per 100 PY 
for otitis media and 
sinusitis:
Anti-TNF = 1.3
DMARDS = 0
Askling et al.  
(LORHEN), 
2007,[38] Ann 
Rheum Dis, 
Sweden
Prospective 
observational 
study
___ Anti-TNF 
(ARTIS) = 
12.1
Swedish 
inpatient RA 
register = 15
Anti-TNF= 4,167
Swedish 
inpatient RA 
register = 2,692
Control =  10,295
Anti-TNF group 
= 7,776 PY
Tx with anti-
TNF versus 
controls
There was an 
increase risk of 
infection requiring 
hospitalisation in 
those treated with 
anti-TNF
TNF antagonists 
(crude 
incidence) = 4.7 
(4.2-5.2)
The RR for 
respiratory 
infections on year 
2 was 1.45 (95% 
CI: 1-2.09)
The RR for skin/ 
soft tissue 
infections was 
1.01 (95% CI: 
0.48-2.16)
The RR for joint sepsis 
was 0.17 (95% CI: 
0.67-2.98)
(continued on next page)
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Table 2 – National registries/observational studies of patients with rheumatoid arthritis treated with anti-TNF therapy (continued).
First author, year 
of publication, 
journal title, 
country of origin
Type of study
e.g.: RCT,
cohort, case- 
control, cross 
sectional 
surveys, case 
report, reviews
Mean age (yrs) Disease 
duration (yrs) 
(Mean unless 
otherwise 
stated)
Sample size Duration of 
follow-up 
Study 
population
Key findings Serious 
infections rate  
per 100 PY(95 
% CI) (unless 
otherwise 
stated)
Respiratory 
infection
Skin infection Others
Curtis et al., 
2007,[39]  
Arthritis Rheum, 
United States
Retrospective 
cohort study 
Anti-TNF group 
= 50,
MTX only = 55
__ INF = 792
ETA = 1,201
ADA = 282
17 months,
Observation 
time in anti-
TNF group = 
3,894 PY, MTX 
only = 4,846 PY
Tx with INF, ETA 
or ADA versus 
MTX
Risk of bacterial 
infection requiring 
hospitalization was 
two-fold higher 
overall in the 
exposed versus the 
unexposed group
Exposed group 
= 2.9 
Unexposed group 
= 1.4
25 (29.09%) cases of 
pneumonia/
empyema occurred 
in those exposed 
to anti-TNF 
versus 23 (28.04 
%) in the MTX 
group
23 (26.74%) and 17 
(20.73%) cases 
of cellulitis/soft 
tissue infection 
occurred in those 
receiving anti 
TNF and MTX, 
respectively
Four cases of septic 
arthritis were 
observed in each 
group
Carmona et al. 
(BIOBADASER), 
2007,[40] Ann 
Rheum Dis, Spain
Prospective 
observational 
study
BIOBADASER 
= 53,
EMECAR = 52
_____ BIOBADASER= 
67, EMECAR 
= 67
BIOBADASER = 
2,644 PY,
EMECAR =
2,269 PY
RA patients 
treated and 
not treated 
with TNF 
antagonists
Rate of serious 
infections is 
significantly 
higher in those 
treated with TNF 
antagonists (RR 
1.6).  However, the 
mortality rate ratio 
between the two 
groups was 0.52 
(0.21-1.29)
IR:
BIOBADASER = 4.3 
(3.6-5.2),
EMECAR = 2.8 
(2.2-3.6)
_______ ________ ________
Takeuchi et al. 2008, 
[41] Ann Rheum 
Dis, Japan
Prospective post 
marketing 
surveillance 
study
55.1 9.9 5,000 2,359.34 PY RA patients 
treated with 
infliximab
Tx with INF was well 
tolerated with low 
dose MTX
IR for:
infection = 8.56 
(8.44-8.68)
“respiratory 
disorders” = 1.70 
(1.65-1.75)
Bacterial 
pneumonia = 
2.2%,
PCP = 0.4%,
TB = 0.3%,
Interstitial 
pneumonitis = 
0.5%
Serious ADR = 0.34 
(0.32-0.36)
Serious ADR for 
musculoskeletal = 
0.25 (0.23-0.27)
Favalli et al., 
2009,[42] 
Autoimmunity 
Reviews, Italy
Retrospective 
cohort study
55.84 9.44 1,064 24.21 months Tx with INF, 
ETA, or ADA 
The IR of serious 
infections was 
35.9 per 1,000 PY. 
Age, ESR, and 
use of steroids 
were predictors of 
infection
INF = 3.89 (2.71-
5.07)
ADA = 3.81 (2.14-
5.49)
ETA = 2.56 (1.05-
4.07)
34.3% of infections 
involved the 
lower respiratory 
tract. Five patients 
developed active 
tuberculosis
There were 15  
(20.5%) cases of 
skin and soft 
tissue infections
Seven (9.6%) cases 
of osteoarticular 
infections were 
observed
(continued on next page)
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Table 2 – National registries/observational studies of patients with rheumatoid arthritis treated with anti-TNF therapy (continued).
First author, year 
of publication, 
journal title, 
country of origin
Type of study
e.g.: RCT,
cohort, case- 
control, cross 
sectional 
surveys, case 
report, reviews
Mean age (yrs) Disease 
duration (yrs) 
(Mean unless 
otherwise 
stated)
Sample size Duration of 
follow-up 
Study 
population
Key findings Serious 
infections rate  
per 100 PY(95 
% CI) (unless 
otherwise 
stated)
Respiratory 
infection
Skin infection Others
Galloway et al. 
(BSRBR), 2011, [43] 
Rheumatology, 
United Kingdom
Prospective 
observational 
study
Anti-TNF = 56,
DMARD = 60
Anti-TNF = 11, 
DMARD = 6
Anti-TNF = 
11,798,
nbDMARD = 
3,598
Anti-TNF = 
36,230 PY,
nbDMARD = 
9,259 PY
Tx with anti-
TNF versus 
traditional 
DMARD
There is a small 
significant risk of 
serious infections 
for patients treated 
with anti-TNF.
Ĺage was an 
independent risk 
factor for sepsis in 
both groups. The 
adjusted hazard 
risk was 1.2 (95% 
CI 1.1-1.5), and the 
risk was highest in 
the first 180 days of 
treatment
Anti-TNF = 4.2 
(4-4.4)
nb DMARD = 3.2 
(2.8-3.6)
_____   ______ ______
Komano et al. 
(REAL), 2011,[44] 
J Rheumatol, 
Japan
Prospective 
hospital-based 
observational 
study
Exposed = 58.3
Unexposed 61.4
Exposed = 9.5
Unexposed 
= 9.2
Exposed = 646
Unexposed =
498
Exposed = 592.4 
PY
Unexposed = 
454.7 PY
Tx with anti-
TNF versus nb 
DMARD
Anti-TNF is 
associated with 
increased risk of 
serious infections 
in comparison to 
traditional DMARD
Anti-TNF = 6.42,
Traditional 
DMARD =  2.64
Exposed = 23, 
Unexposed= 9.
The crude IRR was 
1.96 (0.91-4.24)
Exposed = 9,
Unexposed = 1
Bone and joint (one  
for each)
Titton et al. 
(BiobadaBrasil), 
2011, [45] Rev 
Bras Reunmatol, 
Brazil
Prospective 
observational 
study
47.3 Biologic =
10.8
DMARD = 9.6
1,037 2.09 years Tx with 
biological 
agent versus 
traditional 
DMARD
Higher frequency of 
infections in the 
group treated with 
biological agent
________ Exposed = 28.6% Exposed =18.9% Urinary tract = 27.6%
DMARD, disease-modifying antirheumatic drug, URTI, upper respiratory tract infection; HR, hazard ratio; RR*, rate ratio; IRR, incidence rate ratio; INF, infliximab; ETA, Etanercept; ADA, adalimumab; FU, 
follow up; RR, relative risk; PY, patient-years; IR, incidence rate; PCP, pneumocystis jiroveci pneumonia; TB, Tuberculosis; ADR, adverse drug reaction; IR, incidence rate; ESR, erythrocyte sedimentation rate.
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by the short duration of follow-up; in addition, infection of 
the respiratory tract, urinary system, and diverticular ab-
scess which were more common in the elderly, were exclud-
ed from the definition of serious bacterial infection.
Kievit et al.33 recently performed a multi-center data 
registry (DREAM) of RA patients treated with anti-TNF. The 
study included 1,560 patients, and the mean follow-up was 
33 to 40 months. 174 patients were followed-up for at least 
five years. The mean disease duration range was 5.5 to 6.2. 
The incidence rate of serious infections was 2.9 per 100 
patient-years. This was lower than that reported in other 
registries.
Conversely, in 2005 Listing et al.34 performed a 12-month 
prospective observational cohort study using the Ger-
man biologic register (RABBIT), where 858 patients treated 
with anti-TNF were compared to controls on conventional 
DMARDs. The authors reported a more than two-fold in-
crease in serious infections for patients treated with etaner-
cept (RR: 2.2) and infliximab (RR: 2.1). The risk persisted even 
after adjustment for predictors of infection (i.e. age, CRP, RF 
positivity, and disability). There were significantly more re-
spiratory tract and skin infections in the anti-TNF cohort.
A year latter, Dixon et al.,35 on behalf of the British Soci-
ety for Rheumatology Biologics Register (BSRBR) compared 
the infective risk in 8,659 RA patients treated with anti-TNF 
with 2,170 patients on non-biologic treatment. There were 
significantly more skin and soft tissue infections. How-
ever, the overall risk was similar between those receiving 
anti-TNF and traditional DMARDs. Again, this study showed 
that increases in true infective risk peaks in the first three 
months of anti-TNF treatment.
In another retrospective cohort study, Salliot et al. com-
pared the incidence of serious infection in the same group 
of patients (n = 709) pre- and post-TNF inhibitor treatment.36 
Approximately 60% of patients had RA. During the treat-
ment and control period, the incidence rate of serious in-
fection was 10.5 ± 86.9 and 3.4 ± 38.7 per 100 patient-years, 
respectively. Previous joint surgery and steroids were found 
to be risk factors for infection.
Inanc et al. found an increased risk of infection in a small 
cohort of patients (n = 48) on TNF inhibitor compared to 
those on traditional DMARDs (n = 130).37 The incidence of 
serious infection prior to and during treatment were 7/100 
patient-years and 17/100 patient-years, respectively.
In 2007, Askling et al. performed a similar study using 
data from the Swedish biologic (ARTIS) and inpatient regis-
ters, with 4,167 and 44,496 RA patients, respectively.38 Cross-
referencing methods were applied to calculate the relative 
risk of infection requiring hospitalization. The risk of infec-
tion was 1.43 (95% CI: 1.18 to 1.73), 1.15 (95% CI: 0.88 to 1.51), 
and 0.82 (95% CI: 0.62 to 1.08) in the first, second, and third 
year of TNF antagonist exposure, respectively.
In the United States, Curtis et al.39 conducted a retrospec-
tive study of RA patients comparing the bacterial infections 
in those treated with a TNF inhibitor (n = 2,393) with those 
who received MTX (n = 2,933). Medical records of possible 
bacterial infections were identified and examined by physi-
cians for evidence of definite sepsis. The rates of hospital-
ization in those treated with anti-TNF and MTX were 2.7% 
and 2%, respectively. In the multivariate analysis, bacterial 
infection was respectively two- and four-fold higher overall 
and in the first 180 days in patients treated with anti-TNF 
versus those who were treated with MTX alone.
Carmona et al. compared RA patients (n = 4,459) in the 
Spanish biologic registry (BIOBADASER) with another RA co-
hort (n = 789).40 The relative risk of serious infection in the 
anti-TNF group was significantly higher when compared to 
the other cohort (RR: 1.6).
Takeuchi et al.41 reported the results of a postmarking 
surveillance study where 5,000 RA patients started on inf-
liximab were prospectively monitored for six months. The 
mean age of patients was 55.1 years, with mean disease 
duration of 9.9 years. Bacterial pneumonia occurred in 108 
subjects, whose mean age was 63.5 years. No pneumonic 
complications were observed in patients under 40 years old. 
Multiple logistic regression identified the age range of 60 to 
70 years as one of the risk factors for pneumonia.
In 2009, Favali et al. performed a 24-month prospective 
observational study using the Italian register (LOHREN) with 
1,064 RA patients.42 Comparisons were made between users 
of different types of TNF blockers. The incidence rate was 
35.9 per 100 patient-years. Baseline ESR, use of steroids, and 
age at commencement of anti-TNF therapy were identified 
as predictors of infection.
More recently, Galloway et al. reported the updated BSR-
BR results in which the risk of serious infection in 11,798 
patients treated with anti-TNF therapy was compared with 
3,598 patients on traditional DMARDs.43 The adjusted haz-
ard risk was 1.2 (95% CI: 1.1 to 1.5), and the risk was high-
est in the first 180 days of treatment. Although the relative 
risk of infection did not differ between different age groups, 
the number needed to treat in the first six months for one 
additional serious infection was 25 in those aged under 65 
years (95% CI: 20 to 31) compared to 19 (95% CI: 16 to 23) in 
subjects over 65 years.
In Japan, Komano et al.44 performed a prospective hos-
pital-based observational cohort study (REAL) on 1,144 RA 
patients, comparing the risk of serious bacterial infections 
in patients treated with TNF blockers versus users of non-
biologic DMARDs. The crude incidence rate ratio of serious 
infections in the exposed group as compared to the unex-
posed group was 2.43 (95% CI: 1.27 to 4.65).
In 2011, Titton et al.45 reported the preliminary results 
of the Brazilian biologic registry, where 1,037 patients 
treated with biological therapy were compared to 287 
controls on conventional DMARDs. 72% of the patients 
were female, with mean age of 47.3 years. The mean expo-
sure to treatment was 2.09 years. Of the 723 RA patients, 
466 were treated with biological therapy while 257 were 
treated with non-biologic DMARDs. 37%, 31%, and 15% of 
RA patients were receiving infliximab, adalimumab, and 
etanercept, respectively. 8%, 6%, and 4% were treated with 
abatacept, rituximab, and tocilizumab, respectively. Over-
all, infection occurred in 23% of those treated with bio-
logical agents. Upper respiratory tract, urinary tract, and 
soft tissue were the commonest sites of infection. There 
were three cases of active TB: one pulmonary and two dis-
seminated.
The characteristics of the included studies are displayed 
in Table 2. 
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Meta-analysis
A recent meta-analysis46 of randomized controlled trials of the 
safety of TNF blockers in over 8,800 RA patients did not identify 
an increase risk of serious bacterial infection in the normal rec-
ommended dose (Table 3). However, a dose response increase 
in sepsis was observed with high dose biological therapy. The 
odds ratio for serious infection with anti-TNF agents was 2.08 
for studies of 12 weeks duration compared with 0.97 for those 
with follow-up of 104 weeks. Another meta-analysis by Alonso-
Ruiz et al.47 demonstrated that the relative risk of serious infec-
tions while being treated with TNF antagonist was 1.4 (95% CI: 
0.8 to 2.2).
Conversely, a systematic review and meta-analysis by Bon-
gartz et al.48 found an odds ratio of 2 (95% CI: 1.3 to 3.1) for seri-
ous infections in  RA patients treated with anti-TNF (infliximab 
and adalimumab) versus placebo patients. The number needed 
to harm was 59 (95% CI: 39 to 125) for one additional infection 
within a follow-up period of three to 12 months. In the meta-
analysis of observational studies by Bernasky et al.49 the inves-
tigators reported the pooled adjust relative risk of 1.37 (95% CI: 
1.18 to 1.61) for infection in RA patients on biologic therapy.
Table 3 presents the meta-analysis of randomized/ob-
servational studies on the risk of infection with anti-TNF 
therapy.
Early versus longstanding disease
In early RA patients, the respective rates of serious in-
fection in those treated with etanercept26 and adalimumab31 
were 2.6 and 2.9 events per 100 patient-years, respectively. 
However, for those with established disease, the rates for 
etanercept25 and adalimumab32 were 4.8 and 6 events per 
100 patient-years, respectively.
Elderly RA patients
Previous studies found that increasing age in RA patients is a 
risk factor for sepsis.16,18 Takeuchi et al.41 found an increased 
rate of bacterial pneumonia in those with mean age of 63.5 
years and none in those less than 40 years old. Galloway et 
al.43 reported that in the first 180 days of TNF inhibitor treat-
ment, the number needed to harm in subjects over 65 years 
was 19, compared to 25 in subjects under 65 years. However, 
the result was not confirmed by Schneeweiss et al.19
Types of TNF inhibitor and infections
Infliximab was found to have a preferential risk of TB when 
compared to other TNF blockers. Although Curtis et al.39 
found a stronger association between infliximab and seri-
ous bacterial infections (RR: 2.4; 95% CI: 1.2 to 4.7) when 
compared to etanercept (RR: 1.6; 95% CI: 0.8 to 3.8, this find-
ing was not confirmed by the German34 and Italian42 biologic 
registries. 
Summary of evidence for infection in rheumatoid arthritis 
patients treated with anti-TNF
The results of published studies in RA patients on the in-
fluence of anti-TNF on infection rates are conflicting. 
Some studies suggest that there is a link between anti-
TNF24,31-32,34-43,48-49 and infections in RA, while other studies 
yielded the opposite result.18-19,21-30,46-47 The biology of TNF,8,9 
the dose response relationship between TNF blockers and 
infection,23,46 and the higher risk of serious infection at the 
start of treatment35,38,39,43 would suggest that biological ther-
apies are likely to be linked with sepsis. On balance, the re-
sults suggest that infection in RA patients treated with TNF 
blockers is not always due to the pre-existing disease pro-
cess but rather to symptoms that are due to TNF blockers.
Although previous studies reported a higher relative risk 
of infections,34,39 there are now emerging data with longer 
duration of follow-up from the entire United Kingdom that 
suggest an adjusted hazard risk of 1.2.43 These, considered 
together with other studies that found no increased risk, 
would lead to the conclusion that the magnitude of the risk 
is unlikely to be as high as previously anticipated.
Elderly patients41,43 and those with longstanding dis-
ease25,32 may have a higher rate of serious infections com-
pared to their younger counterparts with early disease.26,31 
Similarly, national registries reported a higher serious in-
fection rate in those with longer disease duration who were 
exposed to anti-TNF34-38,41-44 compared to patients with early 
disease.33
Rheumatoid arthritis, anti-TNF, and neutropenia
Rajakulendran et al.50 found that in their cohort of 133 RA 
patients treated with anti-TNF, 19 patients (14.3%) devel-
Table 3 – Meta-analysis of randomized/ observational 
studies on the risk of infection with anti TNF therapy.
First author,
Year of 
publication,
Journal title, 
Country of 
origin
Method Anti-TNF 
agents
Pooled odds 
ratio (OR)  
(95% CI) 
(unless 
otherwise 
stated)
Leombruno et al., 
2009,[ 46] Ann 
Rheum Dis, 
Canada
Meta-analysis of 
RCT
INF, 
ETA,
ADA
High dose versus 
placebo = 2.1 
(1.3-3.3)
Recommended 
dose versus 
placebo = 1.2 
(0.9-1.6)
Alonso-Ruiz et al., 
2008,[47] BMC 
Musculoskelet 
Disord, Spain
Meta-analysis of 
RCT
INF,
ETA, 
ADA
Relative risk of: 
Serious 
infections = 1.4 
(0.8-2.2)
Infection = 1.9 
(0.9-1.2)
Bongartz et al., 
2006,[48] JAMA, 
United States
Meta-analysis of 
RCT
INF,
ADA
High dose versus 
placebo= 2.3 
(1.5-3.6)
Low dose versus 
placebo= 1.8 
(1.1-3.1)
Bernatsky et 
al., 2010, [49] 
J Rheumatol, 
Canada.
Meta-analysis of 
observational 
studies
_____ Pooled risk ratio 
= 1.37  
(1.18-1.60)
TNF, tumor necrosis factor; RCT, randomized controlled trials; INF, 
infliximab; ETA, etanercept; ADA, adalimumab.
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oped neutropenia (< 2 × 109/L). The median time for the de-
velopment of neutropenia after the initiation of biological 
therapy was three months. However, most patients did not 
require any changes to their anti-TNF treatment. Baseline 
neutrophil count and neutropenia on previous DMARDs 
were found to be predictors of low neutrophil count.
Hasting et al.51 recently reported a retrospective cohort 
study examining the relationship between neutropenia, 
baseline demographics, and clinical features in patients 
with inflammatory arthritis receiving anti-TNF therapy. 
There were a total of 367 patients, of whom 81.2% had RA. 
18.8% of patients had at least one episode of neutropenia (< 
2 × 109/L) while on anti-TNF. 3% had severe neutropenia (< 
0.5 × 109/L). These patients were on stable doses of MTX. Se-
rious infection due to neutropenia occurred in four patients 
(6%). Baseline neutrophil count and previous neutropenia 
were predictors of neutropenia on anti-TNF therapy. The 
time taken for the development of neutropenia after the 
commencement of a TNF inhibitor was 17 weeks. However, 
most patients (81%) were able to remain on their original 
treatment.
In the previously discussed STAR study, the mean white 
blood count (WBC) and neutrophil count both decreased 
during treatment with adalimumab.29 However, the ob-
served changes in WBC were small. Similarly, Keystone et 
al. found that treatment with adalimumab was associated 
with a fall in mean WBC.32
The current British Society for Rheumatology guidelines 
recommend regular monitoring of full blood counts in RA 
patients treated with TNF blockers.52 
Summary of evidence for neutropenia in patients with 
inflammatory arthritis on anti-TNF therapy
Anti-TNF therapy can be associated with development 
of neutropenia shortly after the commencement of treat-
ment.50,51 Most anti-TNF related neutropenia were not com-
plicated by sepsis and did not require any alteration in anti-
TNF treatment.
Rheumatoid arthritis, TNF blockers, and tuberculosis
Results were presented recently from the British biologic 
register of the risk of TB in RA patients receiving TNF an-
tagonist.53 In this prospective cohort study, 10,712 anti-TNF 
treated patients were compared with 3,232 RA patients on 
traditional DMARDs. The duration of follow up in the an-
ti-TNF group was 3.21 years compared to 2.30 years in the 
DMARDs. There were 40 cases of TB, all of which occurred 
in the anti-TNF treated patients. 38% (15 cases) were pul-
monary while 62% (25 cases) were extra-pulmonary. Of the 
40 cases, 13 occurred within three months of treatment dis-
continuation. The incidence rate ratio (IRR) with etanercept 
at baseline was 4.2 (95% CI: 1.4 to 12.4) and 3.1 (95% CI: 1 to 
9.5), respectively for adalimumab and infliximab. Patients of 
Asian origin had a six-fold higher risk of TB compared to 
their white counterparts. The number needed to harm was 
600 in the monoclonal antibodies group (adalimumab) com-
pared to TNF receptor blockers (etanercept).  
In the French Research Axed on Tolerance of Biotherapies 
(RATIO) registry, 69 cases of TB were identified.54 Of these, 40 
patients had RA. The results showed that the standardized 
incidence ratio for infliximab (18.6 [95% CI: 13.4 TO 25.8) and 
adalimumab (29.3 [95% CI: 20.3 to 42.4]) were higher com-
pared to etanercept (1.8 [95% CI: 0.7 to 4.3]).
The Brazilian Society of Rheumatology’s guidelines55 
state that all patients should have baseline chest X-ray and 
tuberculin skin test (PPD) prior to treatment with biologic 
DMARDs. The guidelines also state that patients with PPD 
≥ 5 mm with previous TB on chest X-ray or those who had 
close contact with subjects with active TB should be treat-
ed with a  six months course of isoniazid. This treatment 
should be started one month prior to treatment with anti-
TNF therapy.
In 2007, Gomez-Reino et al.56 found that prior to the im-
plementation of the Spanish Society of Rheumatology’s rec-
ommendations for TB prevention, the IRR was 19 (95% CI: 11 
to 32) in RA patients treated with anti-TNF. However, with 
strict adherence to these recommendations, the IRR fell to 
1.8 (95% CI: 0.28 to 7.1).
Summary of evidence for tuberculosis
The biologic registries found that RA patients treated with 
monoclonal antibodies are at increased risk of TB compared 
to those on TNF receptor blockers. However, with strict ad-
herence to guidelines for prescribing TNF-α blockers, the 
IRR of TB fell and approached that of the normal population.
Health technology appraisals
The current American College of Rheumatology (ACR)57 
guidelines state that biologic agents should not be initi-
ated in those with active bacterial infection and in patients 
with non-healing skin ulcers. The ACR guidelines also rec-
ommend that biologic agents should be withheld prior to 
surgery. The recently updated British Society of Rheumatol-
ogy’s guidelines52 indicated that TNF blockers should not be 
initiated in the presence of sepsis, and that these agents 
should be discontinued in those with active infections. 
TNF antagonists should be used with caution in those with 
previous septic arthritis (native or prosthetic), longstand-
ing infected leg ulcers, bronchiectasis and persistent chest 
infection. In Asia, the Japanese College of Rheumatology’s 
guidelines on the use of biological therapies states that 
treatment with TNF blockers should be withheld in those 
with sepsis.58 Similarly, the Brazilian Society of Rheuma-
tology55 recommends that anti-TNF agents should not be 
initiated in those with active infection or at high risk of 
developing infections.
Discussion
TNF antagonists have revolutionized the management of 
RA patients. However, the use of anti-TNF may lead to in-
creased risk of sepsis. Emerging data from national regis-
tries appear to show an increased risk of serious infection 
in RA patients on TNF blockers.37,38,40,42,43
Previously, the higher risk of infective complications in 
RA has been explained by the use of steroids.59 In the cur-
rent era of anti-TNF with less use of steroids, national reg-
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istries still reported an increased risk of sepsis that could 
not be explained solely by the inherent risk of RA. These, 
taken together with national guidelines would reinforce 
the notion that infection is closely linked to biological 
therapy. Furthermore, previous studies have shown that 
RA patients are at an inherently increased risk of infection 
due to immune dysfunction.15,27
In United Kingdom, the National Institute of Clinical 
Excellence (NICE) and the British Society of Rheumatology 
state that, in order to be eligible for anti-TNF therapy, RA 
patients must have had an adequate trial of two DMARDs, 
one of which should be MTX, and have disease activity 
score (DAS) > 5.1.60 It follows that only patients with more 
severe and refractory disease are given anti-TNF. Patients 
with established disease on anti-TNF may have a higher 
rate of serious infections25,32 when compared to those with 
early disease.26,31 When considered together, this subset of 
patients may need to be carefully monitored for infectious 
complications of biologic therapy. The recently updated 
British Society of Rheumatology’s guidelines61 recom-
mends the use of anti-TNF in RA patients with DAS > 3.2.
RA patients with shorter disease duration are more 
likely to remain in remission after TNF blocker discontinu-
ation when compared to their counterparts with estab-
lished disease.22,62,63 Patients with longstanding disease on 
TNF blockers25,32 may have a higher rate of serious infec-
tions compared to younger patients with early disease.26,31 
The inference that follows is that the earlier introduction 
of anti-TNF may allow for its successful withdrawal after 
remission, hence maximizing the benefit to risk ratio.
The use of anti-TNF may affect the production of protec-
tive antibodies following immunization. However, vaccina-
tions other than live attenuated vaccines should be given to 
patients treated with biologic therapy.64 The ACR guidelines 
recommend yearly Influenza and periodic pneumococcal 
vaccinations in those treated with biologic therapy.57
There is a body of evidence on the causal link between 
steroids and sepsis.17-20 It is therefore important to consider 
steroid dosage reduction when remission is achieved. NICE 
recommends the use of steroids for managing flares and 
to only continue treatment when the long-term complica-
tions of steroids have been discussed. When the disease is 
stable, the DMARDs dosages need to be reduced.65
There are now emerging data on the relationship be-
tween anti-TNF and neutropenia.50,51 RA can also be com-
plicated by Felty’s syndrome, which is characterized by 
splenomegaly and neutropenia. The presence of neutrope-
nia should alert physicians to the need for tighter moni-
toring.
The British53 and French54 registries showed that RA 
patients treated with monoclonal antibodies are at in-
creased risk of TB when compared to those on TNF recep-
tor blockers. Therefore, prior to the initiation of anti-TNF, 
specific history of tuberculosis infection, physical exami-
nation for a BCG scar, and screening tests (Mantoux/chest 
X-ray) need to be performed.61 More recently, the T-Spot 
and QuantiFERON-TB Gold tests are available to detect TB 
infection.66 These tests have higher specificity compared 
to PDD, which can be falsely positive due to previous BCG 
vaccination. The British Thoracic Society Standards of Care 
Committee has issued guidelines for the management of 
Mycobacterium tuberculosis infections in patients due to 
commence TNF blockers.67
Different duration of anti-TNF treatment is likely to be 
a possible explanation for conflicting results observed in 
studies. National registries rather than RCTs may be more 
suitable for evaluating adverse side effects due to their 
longer duration of follow-up. Furthermore, observational 
studies are more reflective of clinical practice due to less 
stringent criteria. However, interpretation of observational 
studies is limited by their non-randomized nature and is 
subject to allocation bias.
The UK guidelines are such that patients with more 
severe disease are given anti-TNF. In other countries, the 
guidelines for the use of these drugs may allow for earlier 
or later treatment with TNF blockers. This could account 
for the differences in infection rates observed in published 
studies. A possible weakness of this review is the unavoid-
able publication bias that might ensue due to the higher 
publication rates of positive rather than negative results.
In conclusion, TNF blockers have revolutionized the way 
RA is managed. However, current evidence suggests that 
anti-TNF treatment in RA is closely linked to infection. Pa-
tients need to be aware of the risk of infection together 
with the established benefits of TNF blockers in order to 
give informed consent for treatment. 
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